Veradermics Inc. announced it has begun enrolling women in a Phase 2/3 clinical trial of its experimental oral treatment for female pattern hair loss.
New Haven-based Veradermics Inc. announced it has begun enrolling women in a Phase 2/3 clinical trial of its experimental oral treatment for female pattern hair loss, marking what the company says is the first late-stage U.S. study of an oral prescription drug for the condition.
The biopharmaceutical firm is studying VDPHL01, an extended-release oral minoxidil tablet designed for women and men with androgenetic alopecia, a progressive hair loss condition affecting about 80 million Americans. The latest trial is expected to enroll more than 500 women nationwide. Veradermics is also conducting two other Phase 3 studies and a separate Phase 2 safety and efficacy trial, with full results anticipated in 2026.
The progress follows Veradermics’
$150 million Series C financing round announced in October, which more than doubled the company’s previous funding. The oversubscribed round was led by SR One, and investor Katarina Pance joined the company’s board. Proceeds are supporting VDPHL01’s Phase 3 development.
Preliminary data from the male cohort in an ongoing Phase 2 study showed visible and measurable hair growth within two months, according to the company.
Dr. Maryanne Makredes Senna, a dermatologist at Beth Israel Lahey Health and a member of Veradermics’ scientific advisory board, said the female trial brings long-needed clinical rigor to a condition with few proven treatment options. Currently, topical minoxidil is the only Food and Drug Administration-approved therapy for women.
Veradermics is led by
CEO Dr. Reid Waldman.
